LeonaBio, Inc. logo

LeonaBio, Inc.

LONA

NASDAQHealthcareBiotechnology

Latest quote

$7.73

+$0.045 · +0.59%

Aug 24, 4:00 PM ET

After-hours

$7.73

$0.00 · 0.00%

Aug 24, 4:10 PM ET

LONA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

45

Fair Value

Momentum

72

Gaining

Sentiment

63

Bullish

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Mark J. Litton
Listed since
Sep 18, 2020
Employees
19

Market position

Day range

Current $7.73

52-week range

Current $7.73

Open
$7.57
Previous close
$7.685
Volume
8.29K
0.22× average
Average volume
38.43K
Average daily volume
Market cap
30.49M USD
Beta
2.04
Market reference 1
50-day average
$6.75
+14.52% above average
200-day average
$6.75
+14.52% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
-36.11M USD
P/E (TTM)
-0.24×
P/B (TTM)
0.98×
P/S (TTM)
EV / EBITDA
1.09×
Earnings yield
-326.28%
Free cash flow yield
-141.28%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-380.03%
Return on assets
-114.60%
Return on invested capital
-226.69%

Financial health

Debt / equity
0.02×
Current ratio
1.88×
Altman Z-score
-15.25
Piotroski F-score
1 of 9

Financial statements

Income trends

Operating income

−102.27M USD-1.35%

Net income

−105.61M USD-8.94%
Income trends across reported periods−47.79M USD−76.04M USD−104.28M USD−132.53M USDOperating income, FY2021: −64.02M USDOperating income, FY2022: −104.02M USDOperating income, FY2023: −125.47M USDOperating income, FY2024: −100.9M USDOperating income, FY2025: −102.27M USDNet income, FY2021: −54.85M USDNet income, FY2022: −95.64M USDNet income, FY2023: −117.67M USDNet income, FY2024: −96.94M USDNet income, FY2025: −105.61M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −64.02M USD. Operating income FY2022 −104.02M USD. Operating income FY2023 −125.47M USD. Operating income FY2024 −100.9M USD. Operating income FY2025 −102.27M USD. Net income FY2021 −54.85M USD. Net income FY2022 −95.64M USD. Net income FY2023 −117.67M USD. Net income FY2024 −96.94M USD. Net income FY2025 −105.61M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold68.09M USD479K USD
Gross profit−68.09M USD−479K USD
Research and development17.5M USD70.68M USD93.79M USD61.46M USD42.79M USD
Selling, general, and administrative16.68M USD26.09M USD33.3M USD32.55M USD21.23M USD
Operating expenses34.18M USD100.9M USD125.47M USD104.02M USD63.54M USD
Interest income3.96M USD7.64M USD3.22M USD337K USD
Interest expense24.32M USD3K USD
Depreciation and amortization972K USD970K USD969K USD845K USD479K USD
Operating income−102.27M USD−100.9M USD−125.47M USD−104.02M USD−64.02M USD
Net income−105.61M USD−96.94M USD−117.67M USD−95.64M USD−54.85M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
18%
2 beats, 8 misses, 1 met estimate
Average EPS surprise
-468.90%
11 comparable reports
Latest EPS result
-0.8
Estimate -1.39 · Beat by 42.40%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.38-7.05-13.73-20.4Q1 '25MissQ2 '25MissQ3 '25MetQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual -3.9, estimate -0.45, surprise -766.67%, Miss. Q2 2025, reported May 9, 2025: actual -2.3, estimate -2, surprise -15.00%, Miss. Q3 2025, reported Aug 7, 2025: actual -1.8, estimate -1.8, surprise 0.00%, Met estimate. Q4 2025, reported Nov 6, 2025: actual -1.68, estimate -1.06, surprise -58.49%, Miss. Q1 2026, reported Mar 26, 2026: actual -18.92, estimate -1.35, surprise -1300.34%, Miss. Q2 2026, reported May 7, 2026: actual -1.73, estimate -2.28, surprise +24.03%, Beat. Q3 2026, reported Aug 14, 2026: actual -0.8, estimate -1.39, surprise +42.40%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.685, surprise —, Comparison unavailable.

LONA news

Corporate actions

Corporate action history

Stock split

Effective Sep 18, 2025

1:10

LONA peers

ETFs holding LONA

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research LONA

research.disclaimer